Predict your next investment

HEALTHCARE | Disease Diagnosis

See what CB Insights has to offer

Founded Year

2017

Stage

Seed | Alive

Total Raised

$820K

Last Raised

$400K | 2 yrs ago

About PROMISS Diagnostics

PROMISS Diagnostics develops a proprietary algorithm that uses data on calcium, albumin, age, and menopause to distinguish cancerous masses in the ovary from benign masses.

PROMISS Diagnostics Headquarter Location

1225 Discovery Pkwy Ste 220

Milwaukee, Wisconsin, 53226,

United States

Latest PROMISS Diagnostics News

Milwaukee-based PROMISS Diagnostics raises $400,000

Jan 10, 2020

Funding round led by Wisconsin Alumni Research Foundation By Share PROMISS Diagnostics, Inc., a Milwaukee-based company developing an early-detection ovarian cancer test, has raised $400,000 in a seed round of funding, the company announced Friday. The funding round was led by the Wisconsin Alumni Research Foundation with additional investments from Cream City Venture Capital , Northwestern Mutual’s $5 million venture fund. PROMISS Diagnostics is a venture-stage biotech company that develops bio-analytical solutions to assist physicians in improving women’s health outcomes. PROMISS Diagnostics president and chief executive office Jalal Sulaiman founded the company in 2017. Its first-generation multi-analyte blood test (named PROMISS, for “Predicting Risk of Ovarian Malignancy in Serum Samples”) distinguishes malignant from benign ovarian masses. The seed round will enable the company to develop and optimize the PROMISS technology as a predictive ovarian cancer diagnostic tool. “This funding will allow us to make big strides in developing the PROMISS test and move us closer to the market where it will significantly improve cancer diagnosis,” Sulaiman said. PROMISS is a proprietary machine learning algorithm that uses common serum biomarkers and patient data to diagnose ovarian cancer in women with a pelvic mass. The algorithm inputs are readily available, which means PROMISS is potentially a low-cost, highly accurate, point-of-care diagnostic tool that could be especially useful in low resource areas like rural American, where ovarian cancer mortality is the highest, according to a press release. “PROMISS Diagnostics seeks to radically transform this paradigm with its innovative technology,” Sulaiman said. “We are passionate about improving patient outcomes by developing innovative tools that are efficacious, inexpensive and accessible.” BizTimes Daily

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PROMISS Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PROMISS Diagnostics is included in 4 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

947 items

Startups focused on providing products and services catering to women's health and wellbeing.

M

Medical Devices

7,401 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health & Wellness Assessment

2,359 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.